Clinical Trials Browser

Interventional × spartalizumab × Gynecologic × Clear all

Fibrolamellar hepatocellular carcinoma, Carcinoma, Non-Small-Cell Lung, Hemangiosarcoma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

NCT07472153 2026-03-16

PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer

Phase 2/3 Recruiting

120 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT07319429 2026-03-13

FEMUS

Phase 2/3 Recruiting

260 enrolled

Gynecologic

Endometrial Neoplasms

NCT05824468 2026-03-10

Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer

Phase 2 Active not recruiting

30 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT05941507 2025-09-24

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

Phase 1/2 Recruiting

300 enrolled

BreastCNSGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Glioblastoma, Head and Neck Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT03104699 2025-07-30

A Study of AGEN2034 in Advanced Tumors and Cervical Cancer

Phase 1/2 Completed

211 enrolled 29 charts

Gynecologic

Uterine Cervical Neoplasms

NCT03294694 2025-05-31

Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer

Phase 1 Terminated

33 enrolled

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms

NCT04152018 2025-05-28

Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

Phase 1 Terminated

85 enrolled

GastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Bile Duct Neoplasms, Carcinoma, Renal Cell, Esophageal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT04802876 2025-03-21

ACROPOLI

Phase 2 Active not recruiting

184 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Adenocarcinoma Of Esophagus, Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Uveal Melanoma, Anus Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasms, Unknown Primary, Sarcoma, Thyroid Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03549000 2024-12-13

A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.

Phase 1 Terminated

127 enrolled

BreastGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT04672434 2024-12-09

Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies

Phase 1 Completed

48 enrolled

GastrointestinalGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Uterine Cervical Neoplasms, Esophageal Neoplasms, Mesothelioma, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT03757858 2024-02-07

Hyperthermia Combined With Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or Metastases

Phase 1/2 Completed

40 enrolled

Gynecologic

Neoplasm Metastasis, Neoplasms, Pelvic Neoplasms

NCT04864782 2024-01-12

QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer

Phase 2/3 Terminated

46 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT05511623 2023-09-11

Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical Cancer

Phase 2 Recruiting

112 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT02607813 2022-12-21

Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations

Phase 1 Terminated

142 enrolled

DermatologicGynecologic

Melanoma, Ovarian Neoplasms

NCT04943627 2022-10-05

Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)

Phase 3 Withdrawn

Gynecologic

Uterine Cervical Neoplasms

NCT02807844 2021-08-11

Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies

Phase 1/2 Completed

141 enrolled 58 charts

BreastDermatologicGastrointestinalGynecologic

Melanoma, Pancreatic Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04368273 2020-04-29

CCRT+PD-1

Phase 1/2 Unknown

30 enrolled

Gynecologic

Uterine Cervical Neoplasms

Clinical Trials

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer

FEMUS

Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

A Study of AGEN2034 in Advanced Tumors and Cervical Cancer

Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer

Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

ACROPOLI

A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.

Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies

Hyperthermia Combined With Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or Metastases

QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer

Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical Cancer

Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations

Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)

Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies

CCRT+PD-1